Exagen has extended its collaboration agreement with GlaxoSmithKline (GSK) to raise awareness of the importance of timely diagnosis of systemic lupus erythematosus (SLE), the most common and severe form of lupus.
Exagen announced a new study in collaboration with Brigham and Women’s Hospital in Boston, MA. This study will evaluate the incidence and risk factors for onset of rheumatic autoimmune diseases in people who recovered from COVID-19.
Exagen has entered into a strategic partnership with Sonora Quest. The agreement provides preferred access through Sonora Quest in Arizona to Exagen’s AVISE testing.
Both Exagen and GSK share a common goal to help SLE patients shorten the time to their diagnosis, which is nearly six years on average, and to facilitate improved patient health outcomes.